Dosing guidance for intravenous colistin in critically-ill patients.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background.: Intravenous colistin is difficult to use because plasma concentrations for antibacterial effect overlap those causing nephrotoxicity, and there is large interpatient variability in pharmacokinetics. The aim was to develop dosing algorithms for achievement of a clinically desirable average steady-state plasma colistin concentration (Css,avg) of 2 mg/L. Methods.: Plasma concentration-time data from 214 adult critically ill patients (creatinine clearance, 0–236 mL/min; 29 receiving renal replacement therapy [RRT]) were subjected to population pharmacokinetic analysis. Development of an algorithm for patients not receiving RRT was based on the relationship between the dose of colistimethate that would be needed to achieve a desired Css,avg and creatinine clearance. The increase in colistin clearance when patients were receiving RRT was determined from the population analysis and guided the supplemental dosing needed. To balance potential antibacterial benefit against risk of nephrotoxicity the algorithms were designed to achieve target attainment rates of >80% for Css,avg ≥2 and <30% for Css,avg ≥4 mg/L. Results.: When algorithm doses were applied back to individual patients not receiving RRT (including those prescribed intermittent dialysis on a nondialysis day), >80% of patients with creatinine clearance <80 mL/min achieved Css,avg ≥2 mg/L, but for patients with creatinine clearance ≥80 mL/min, the target attainment was <40%, even with the maximum allowed daily dose of 360 mg colistin base activity. For patients receiving RRT, target attainment rates were >80% with the proposed supplemental dosing. In all categories of patients, <30% of patients attained Css,avg ≥4 mg/L. Conclusions.: The project has generated clinician-friendly dosing algorithms and pointed to circumstances in which intravenous monotherapy may be inadequate.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Self-citationGaronzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., & Nation, R. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01733-10 · Cited by 696
Self-citationSandri, A. M., Landersdorfer, C. B., Jacob, J., Boniatti, M. M., Dalarosa, M. G., Falci, D. R., Behle, T. F., Bordinhão, R. C., Wang, J., Forrest, A., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit334 · Cited by 430
Self-citationColistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa
Bergen, P. J., Li, J., Rayner, C. R., & Nation, R. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00035-06 · Cited by 366
Self-citationPogue, J. M., Lee, J., Marchaim, D., Yee, V., Zhao, J. J., Chopra, T., Lephart, P., & Kaye, K. S. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir611 · Cited by 327
Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?
Nation, R. L., Velkov, T., & Li, J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu213 · Cited by 310
Self-citationSorlí, L., Luque, S., Grau, S., Berenguer, N., Segura, C., Montero, M. M., Álvarez-Lerma, F., Knobel, H., Benito, N., & Horcajada, J. P. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-380 · Cited by 225
Cheah, S.-E., Wang, J., Nguyen, V. T. T., Turnidge, J. D., Li, J., & Nation, R. L. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv267 · Cited by 206
Self-citationUpdated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?
Nation, R. L., Garonzik, S. M., Li, J., Thamlikitkul, V., Giamarellos-Bourboulis, E. J., Paterson, D. L., Turnidge, J. D., Forrest, A., & Silveira, F. P. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ964 · Cited by 168
Self-citation
Research works printed but not linked: 2
- Forrest, Toxicodynamics for colistin-associated changes in creatinine clearance. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; 5–9 September 2014
- European Medicines Agency, Annex III: amendments to relevant sections of the summary of product characteristics and the package leaflets
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Tsuji, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., Giacobbe, D. R., Viscoli, C., Giamarellou, H., Karaiskos, I., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2209 · Cited by 949
Self-citationHorcajada, J. P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N., & Grau, S. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-19 · Cited by 961
Paul, M., Daikos, G. L., Durante-Mangoni, E., Yahav, D., Carmeli, Y., Benattar, Y. D., Skiada, A., Andini, R., Eliakim-Raz, N., Nutman, A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30099-9 · Cited by 623
Rescuing the Last-Line Polymyxins: Achievements and Challenges
Nang, S. C., Azad, M. A. K., Velkov, T., Zhou, Q. (., & Li, J. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000020 · Cited by 421
Self-citationHawkey, P. M., Warren, R. E., Livermore, D. M., McNulty, C. A. M., Enoch, D. A., Otter, J. A., & Wilson, A. P. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky027 · Cited by 334
The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
Karaiskos, I., Lagou, S., Pontikis, K., Rapti, V., & Poulakou, G. (2019) · Frontiers in Public Health · doi:10.3389/fpubh.2019.00151 · Cited by 288
Wright, H., Bonomo, R. A., & Paterson, D. L. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.09.001 · Cited by 256
Self-citationGlobal Burden of Colistin-Resistant Bacteria: Mobilized Colistin Resistance Genes Study (1980–2018)
Elbediwi, M., Li, Y., Paudyal, N., Pan, H., Li, X., Xie, S., Rajkovic, A., Feng, Y., Fang, W., C. Rankin, S., et al. (2019) · Microorganisms · doi:10.3390/microorganisms7100461 · Cited by 257
Satlin, M. J., Lewis, J. S., Weinstein, M. P., Patel, J., Humphries, R. M., Kahlmeter, G., Giske, C. G., & Turnidge, J. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa121 · Cited by 250
Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment
Piperaki, E.-T., Tzouvelekis, L. S., Miriagou, V., & Daikos, G. L. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.03.014 · Cited by 240
Clinical Pharmacokinetics and Pharmacodynamics of Colistin
Grégoire, N., Aranzana-Climent, V., Magréault, S., Marchand, S., & Couet, W. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0561-1 · Cited by 191
Sumi, C. D., Heffernan, A. J., Lipman, J., Roberts, J. A., & Sime, F. B. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00791-z · Cited by 181
Management of KPC-producing Klebsiella pneumoniae infections
Bassetti, M., Giacobbe, D. R., Giamarellou, H., Viscoli, C., Daikos, G. L., Dimopoulos, G., De Rosa, F. G., Giamarellos-Bourboulis, E. J., Rossolini, G. M., Righi, E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.08.030 · Cited by 175
Self-citationKlebsiella pneumoniae: Virulence, Biofilm and Antimicrobial Resistance
Piperaki, E., Syrogiannopoulos, G. A., TZOUVELEKIS, L. S., & Daikos, G. L. (2017) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001675 · Cited by 172
Resensitizing carbapenem- and colistin-resistant bacteria to antibiotics using auranofin
Sun, H., Zhang, Q., Wang, R., Wang, H., Wong, Y.-T., Wang, M., Hao, Q., Yan, A., Kao, R. Y. T., Ho, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18939-y · Cited by 173
Comprehensive Guidance for Antibiotic Dosing in Obese Adults
Meng, L., Mui, E., Holubar, M. K., & Deresinski, S. C. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2023 · Cited by 153
Landersdorfer, C. B., Wang, J., Wirth, V., Chen, K., Kaye, K. S., Tsuji, B. T., Li, J., & Nation, R. L. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx409 · Cited by 143
Self-citationManagement of post-neurosurgical meningitis: narrative review
Hussein, K., Bitterman, R., Shofty, B., Paul, M., & Neuberger, A. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.05.013 · Cited by 142
Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity
Nation, R. L., Rigatto, M. H., Falci, D. R., & Zavascki, A. P. (2019) · Antibiotics · doi:10.3390/antibiotics8010024 · Cited by 140
Self-citationPolymyxin Resistance in Gram-negative Pathogens
Srinivas, P., & Rivard, K. R. (2017) · Current Infectious Disease Reports · doi:10.1007/s11908-017-0596-3 · Cited by 154
Pistolesi, V., Morabito, S., Mario, F. D., Regolisti, G., Cantarelli, C., & Fiaccadori, E. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00583-19 · Cited by 125
Mushtaq, S., Sadouki, Z., Vickers, A. A., Livermore, D. M., & Woodford, N. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01582-20 · Cited by 119
Polymyxins for CNS infections: Pharmacology and neurotoxicity
Velkov, T., Dai, C., Ciccotosto, G. D., Cappai, R., Hoyer, D., & Li, J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.012 · Cited by 111
Self-citationBrennan-Krohn, T., Pironti, A., & Kirby, J. E. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00873-18 · Cited by 110
Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children
Chiotos, K., Hayes, M., Gerber, J. S., & Tamma, P. D. (2019) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piz085 · Cited by 98
Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients
Miglis, C. M., Rhodes, N. J., Avedissian, S. N., Kubin, C. J., Yin, M. T., Nelson, B. C., Pai, M. P., & Scheetz, M. H. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01475-17 · Cited by 92
on behalf of the Magic Bullet Working Group WP1, Cisneros, J. M., Rosso-Fernández, C. M., Roca-Oporto, C., PASCALE, G. D., Jiménez‐Jorge, S., Fernández-Hinojosa, E., Matthaiou, D. K., Ramírez, P., Díaz-Miguel, R. O., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2627-y · Cited by 91
Optimizing Antimicrobial Drug Dosing in Critically Ill Patients
Póvoa, P. M. S. R., Moniz, P., Gonçalves-Pereira, J., & Coelho, L. (2021) · Microorganisms · doi:10.3390/microorganisms9071401 · Cited by 91
Gajdács, M., Bátori, Z., Ábrók, M., Lázár, A., & Burián, K. (2020) · Life · doi:10.3390/life10020016 · Cited by 85
Molecular Mechanisms of Neurotoxicity Induced by Polymyxins and Chemoprevention
Dai, C., Xiao, X., Li, J., Ciccotosto, G. D., Cappai, R., Tang, S., Schneider‐Futschik, E. K., Hoyer, D., Velkov, T., & Shen, J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00300 · Cited by 86
Self-citationMurray, M., Guillermo Salvatierra, R., Dávila-Barclay, A., Ayzanoa, B., Castillo-Vilcahuaman, C., Huang, M., Pajuelo, M. J., Lescano, A. G., Cabrera, L., Calderon, M. M., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.635871 · Cited by 82
Forrest, A., Merali, S. J., Thamlikitkul, V., Giamarellos‐Bourboulis, E. J., Paterson, D. L., Li, J., Silveira, F. P., & Nation, R. L. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01367-17 · Cited by 76
Self-citationLin, Y.-W., Zhou, Q. T., Onufrak, N. J., Wirth, V., Chen, K., Wang, J., Forrest, A., Chan, H., & Li, J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00211-17 · Cited by 74
Self-citationThe Epidemiology, Evolution, and Treatment of KPC-Producing Organisms
Porreca, A. M., Sullivan, K. V., & Gallagher, J. C. (2018) · Current Infectious Disease Reports · doi:10.1007/s11908-018-0617-x · Cited by 86
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections
Iovleva, A., Fowler, V. G., & Doi, Y. (2024) · Drugs · doi:10.1007/s40265-024-02104-6 · Cited by 75
Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria
Shields, R. K., Anand, R., Clarke, L. G., Paronish, J., Weirich, M. P., Perone, H., Kieserman, J. M., Freedy, H. R., Andrzejewski, C., & Bonilla, H. F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173286 · Cited by 71
Han, M., Zhu, Y., Creek, D. J., Lin, Y., Gutu, A. D., Hertzog, P. J., Purcell, T., Shen, H., Moskowitz, S. M., Velkov, T., et al. (2019) · mSystems · doi:10.1128/msystems.00149-18 · Cited by 73
Self-citationSusceptibility Testing for the Polymyxins: Two Steps Back, Three Steps Forward?
Vasoo, S. S. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00888-17 · Cited by 72
Singh, S., Menon, V. P., Mohamed, Z. U., Kumar, V. A., Nampoothiri, V., Sudhir, S., Moni, M., Dipu, T. S., Dutt, A., Edathadathil, F., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy290 · Cited by 68
“To standardize dosing for colistin and polymyxin B, the ASP team established guidelines for loading dose and maintenance dose based on creatinine clearance [12, 13].”
MethodGajdács, M., & Urbán, E. Z. (2019) · Diseases · doi:10.3390/diseases7020041 · Cited by 65
Considerations for the optimal management of antibiotic therapy in elderly patients
Falcone, M., Paul, M., Tiseo, G., Yahav, D., Prendki, V., Friberg, L. E., Güerri‐Fernández, R., Gavazzi, G., Mussini, C., & Tinelli, M. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.02.022 · Cited by 64
Sorlí, L., Luque, S., Li, J., Campillo, N., Danés-Castells, M., Montero, M., Segura, C., Grau, S., & Horcajada, J. P. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.06.011 · Cited by 55
Self-citationDai, C., Wang, Y., Sharma, G., Shen, J., Velkov, T., & Xiao, X. (2020) · Antioxidants · doi:10.3390/antiox9060506 · Cited by 55
Updated antimicrobial dosing recommendations for obese patients
Castro‐Balado, A., Varela-Rey, I., Mejuto, B., Mondelo‐García, C., Zarra‐Ferro, I., Rodríguez-Jato, T., & Fernández‐Ferreiro, A. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-23 · Cited by 60
Comprehensive guidance for antibiotic dosing in obese adults: 2022 update
Meng, L., Mui, E., Ha, D. R., Stave, C. D., Deresinski, S. C., & Holubar, M. K. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2769 · Cited by 51
Pogue, J. M., Jones, R. N., Bradley, J. S., Andes, D. R., Bhavnani, S. M., Drusano, G. L., Dudley, M. N., Flamm, R. K., Rodvold, K. A., & Ambrose, P. G. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01495-19 · Cited by 55
Monogue, M. L., & Nicolau, D. P. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx483 · Cited by 48
Polymyxins: To Combine or Not to Combine?
Pérez, F., Chakhtoura, N. G. E., Yasmin, M., & Bonomo, R. A. (2019) · Antibiotics · doi:10.3390/antibiotics8020038 · Cited by 48
Giacobbe, D. R., Mikulska, M., & Viscoli, C. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1549487 · Cited by 47
The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
Aslan, A. T., & Akova, M. (2022) · Antibiotics · doi:10.3390/antibiotics11020277 · Cited by 52
Pharmacokinetics and pharmacodynamics of peptide antibiotics
Bian, X., Qu, X., Zhang, J., Nang, S. C., Bergen, P. J., Zhou, Q. T., Chan, H., Feng, M., & Li, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114171 · Cited by 47
Self-citationChallenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review
Rychlíčková, J., Kubíčková, V., Suk, P., & Urbánek, K. (2023) · Antibiotics · doi:10.3390/antibiotics12030437 · Cited by 44
Heffernan, A. J., Lim, S. M. S., Lipman, J., & Roberts, J. A. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100970 · Cited by 48
Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of Pseudomonas aeruginosa
Kothari, A., KHERDEKAR, R. S., Mago, V., Uniyal, M., Mamgain, G., Kalia, R. B., Kumar, S., Jain, N. K., Pandey, A., & Omar, B. J. (2023) · Pharmaceuticals · doi:10.3390/ph16091230 · Cited by 41
Kristoffersson, A., Rognås, V., Brill, M. J. E., Dishon‐Benattar, Y., Durante‐Mangoni, E., Daitch, V., Skiada, A., Lellouche, J., Nutman, A., Kotsaki, A., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.03.016 · Cited by 41
Yang, Q., Pogue, J. M., Li, Z., Nation, R. L., Kaye, K. S., & Li, J. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.08.003 · Cited by 40
Self-citationSatlin, M. J. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01608-18 · Cited by 40
Xie, Y., Jin, X., Yan, S., Wu, C., Xiang, B.-X., Wang, H., Liang, W., Yang, B.-C., Xiao, X., Li, Z., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.967412 · Cited by 39
Next-Generation Polymyxin Class of Antibiotics: A Ray of Hope Illuminating a Dark Road
Aslan, A. T., Akova, M., & Paterson, D. L. (2022) · Antibiotics · doi:10.3390/antibiotics11121711 · Cited by 38
Self-citationMoni, M., Sudhir, A. S., Sathyapalan, D. T., Mohamed, Z. U., Prabhu, B., Edathadathil, F., Balachandran, S., Singh, S. K., Prasanna, P., Menon, V. P., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.08.010 · Cited by 37
Shifting Gears: The Future of Polymyxin Antibiotics
Lenhard, J. R., Bulman, Z. P., Tsuji, B. T., & Kaye, K. S. (2019) · Antibiotics · doi:10.3390/antibiotics8020042 · Cited by 37
Nakwan, N., Chokephaibulkit, K., & Imberti, R. (2019) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002448 · Cited by 36
Zheng, J.-Y., Huang, S.-S., Huang, S.-H., & Ye, J.-J. (2019) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2019.08.007 · Cited by 37
Zhou, Y., Liu, P., Zhang, C.-J., Liao, X., Sun, J. G., & Liu, Y. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02957 · Cited by 36
Lim, S. M. S., Sime, F. B., & Roberts, J. A. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.02.016 · Cited by 38
Gajdács, M. (2020) · Antibiotics · doi:10.3390/antibiotics9040153 · Cited by 35
Matusik, É., Boidin, C., Friggeri, A., Richard, J., Bitker, L., Roberts, J. A., & Goutelle, S. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000941 · Cited by 37
Therapeutic options for difficult-to-treat Acinetobacter baumanniiinfections: a 2020 perspective
Bassetti, M., Labate, L., Russo, C., Vena, A., & Giacobbe, D. R. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1817386 · Cited by 36
Xie, J., Roberts, J. A., Lipman, J., Cai, Y., Wang, H., Zhao, N.-N., Xu, X., Yang, S., Li, Y., & Zhang, K. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105943 · Cited by 31
Danis-Wlodarczyk, K. M., Cai, A., Chen, A., Gittrich, M. R., Sullivan, M. B., Wozniak, D. J., & Abedon, S. T. (2021) · Pharmaceuticals · doi:10.3390/ph14111162 · Cited by 33
Polymyxin B causes DNA damage in HK-2 cells and mice
Yun, B., Zhang, T., Azad, M. A. K., Wang, J., Nowell, C. J., Kalitsis, P., Velkov, T., Hudson, D. F., & Li, J. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2192-1 · Cited by 32
Self-citationHeffernan, A. J., Sime, F. B., Taccone, F. S., & Roberts, J. A. (2018) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000494 · Cited by 30
Spapen, H. D., Laethem, J. V., Hites, M., Verdoodt, A., Diltoer, M., & Honoré, P. M. (2019) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2019-0022 · Cited by 29
Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis
Fujii, M., Karumai, T., Yamamoto, R., Kobayashi, E., Ogawa, K., Tounai, M., Lipman, J., & Hayashi, Y. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1750597 · Cited by 32
Marano, V., Marascio, N., Pavia, G., Lamberti, A. G., Quirino, A., Musarella, R., Casalinuovo, F., Mazzitelli, M., Trecarichi, E. M., Torti, C., et al. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104058 · Cited by 28
Colistin nephrotoxicity-age and baseline kidney functions hold the key
Prasannan, B., Mukthar, F., Unni, V., Mohan, S., & Vinodkumar, K. (2021) · Indian Journal of Nephrology · doi:10.4103/ijn.ijn_130_20 · Cited by 28
Nation, R. L., & Forrest, A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-16373-0_15 · Cited by 28
Self-citationBian, X., Liu, X., Feng, M., Bergen, P. J., Li, J., Chen, Y., Zheng, H., Song, S., & Zhang, J. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106271 · Cited by 28
Self-citationA Systematic Review of Pharmacokinetic Studies of Colistin and Polymyxin B in Adult Populations
Zamri, P. J., Lim, S. M. S., Sime, F. B., Roberts, J. A., & Abdul-Aziz, M. H. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01488-2 · Cited by 29
Tsala, M., Vourli, S., Georgiou, P., Pournaras, S., Tsakris, A., Daikos, G. L., Mouton, J. W., & Meletiadis, J. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx522 · Cited by 27
Ooi, M. H., Ngu, S. J., Chor, Y. K., Li, J., Landersdorfer, C. B., & Nation, R. L. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz067 · Cited by 27
Self-citationLong, W.-M., Xu, W.-X., Hu, Q., Qu, Q., Wu, X., Chen, Y., Wan, Q., Xu, T., Luo, Y. Y., & Qu, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1533952 · Cited by 26
Vairo, C., Villar-Vidal, M., Hernández, R. M., Igartúa, M., & Villullas, S. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122739 · Cited by 26
Han, Y., Zhang, Y., Zeng, W., Huang, Z., Cheng, H., Kong, J., Xu, C., Xu, M., Zhou, T., & Cao, J. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106899 · Cited by 26
Lin, Y.-T., Su, C.-F., Chuang, C., Lin, J., Lu, P., Huang, C.-T., Wang, J., Chuang, Y.-C., Siu, L.-K. K., & Fung, C.-P. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy336 · Cited by 26
Brinkmann, A., Röhr, A. C., Frey, O. R., Krüger, W. A., Brenner, T., Richter, D., Bodmann, K. ‐., Kresken, M., & Grabein, B. (2018) · Der Anaesthesist · doi:10.1007/s00101-018-0512-8 · Cited by 25
Jung, S., Chung, E. K., Jun, M. S., Son, E. S., & Rhie, S. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-44965-y · Cited by 25
Qi, B., Gijsen, M., Brantegem, P. V., Vocht, T. D., Deferm, N., Abza, G. B., Nauwelaerts, N., Wauters, J., Spriet, I., & Annaert, P. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2812 · Cited by 25
Surovoy, Y. A., Burkin, M. A., Galvidis, I. A., Sobolev, M. A., Rende, O. C., & Tsarenko, S. V. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03415-x · Cited by 25
An All‐in‐One Nano‐Biomimetic Polyamidoamine Dendrimer Platform for Treatment of CRKP Pneumonia
Duan, S., Li, H., Wang, F., Li, L., Fan, H., Ma, Y., Yu, Q., Li, W., Wu, M. X., Mao, Y., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202401549 · Cited by 25
Koch, B. C. P., Muller, A. E., Hunfeld, N., de Winter, B. C. M., Ewoldt, T. M. J., Abdulla, A., & Endeman, H. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000942 · Cited by 21
Zabidi, M. S., Bakar, R. A., Musa, N., Mustafa, S., & Yusuf, W. N. W. (2021) · Pharmaceuticals · doi:10.3390/ph14090903 · Cited by 24
Lin, Y., Rahim, N. A., Zhao, J., Han, M., Yu, H. H., Wickremasinghe, H., Chen, K., Wang, J., Paterson, D. L., Zhu, Y., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02176-18 · Cited by 23
Self-citationSatlin, M. J. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa065 · Cited by 23
Ehrentraut, S., Muenster, S., Kreyer, S., Theuerkauf, N. U., Bode, C., Steinhagen, F., Ehrentraut, H., Schewe, J., Weber, M., Putensen, C., et al. (2020) · Microorganisms · doi:10.3390/microorganisms8030415 · Cited by 23
Characteristic actions of CDP-choline on the central nervous system.
Yasuhara, M., & Naito, H. (1974) · PubMed · Cited by 23
Witherell, K. S., Price, J., Bandaranayake, A. D., Olson, J. M., & Call, D. R. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.05.013 · Cited by 22
Metadata
- Authors
- Nation, R. L., Garonzik, S. M., Thamlikitkul, V., Giamarellos-Bourboulis, E. J., Forrest, A., Paterson, D. L., Li, J., & Silveira, F. P.
- Affiliations
- Monash University (AU)
- School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo 3 ;
- Siriraj Hospital (TH)
- Fourth Department of Internal Medicine, University of Athens 6 Medical School ,
- University at Buffalo, State University of New York (US)
- The University of Queensland (AU)
- University of Pittsburgh Medical Center (US)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-12-23
- Volume
- 64
- Issue
- 5
- Pages
- 565-571
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC5850520
- OpenAlex
- W2566638444
- Cited by
- 262
- References
- 27
- Citations by year
- 2026: 13 · 2025: 21 · 2024: 18 · 2023: 17 · 2022: 31 · 2021: 27 · 2020: 42 · 2019: 42 · 2018: 27 · 2017: 23
- FWCI
- 24.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI070896)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- colistin, intravenous administration, dosing algorithm, critically ill patients, nephrotoxicity, population pharmacokinetics, creatinine clearance, renal replacement therapy, colistimethate, steady-state plasma concentration, antibiotic dosing
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents, Colistin, Female, Humans, Male, Middle Aged, Pilot Projects, Critical Illness, Practice Guidelines as Topic, Renal Replacement Therapy, Young Adult, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.